Safety and Tolerability of PoliovacSin in Healthy Adult Volunteers

Phase 1, randomised, double-blind trial in poliomyelitis comparing Group 1 PolioVacSin with Group 2 Placebo (2 arms). Primary endpoints: Incidence of Vaccination-Related Adverse Events (AEs) and Serious Adverse Events (SAEs) and Frequency and Severity of Investigator-Observed Solicited Local and Systemic Adverse Reactions Within 7 Days Post-Vaccination. Started Jan 2018; status: completed.